Navigation Links
Scientists Find Potential Weakness In Plague Germ

s, but with no symptoms.

About 36 hours after exposure, the disease progresses into a second phase, with a lot of inflammation and symptoms. Bacteria invade the spleen and other organs and an overwhelming, rapidly developing pneumonia proves fatal.

The researchers focused on a protein known as plasminogen activator, which they think the bacterium uses to break open protective blood clots that the body forms to try to limit the spread of an infection.

They made a mutant version of Yersinia without that protein. When mice were exposed to it, the bacterium managed to begin infection normally but the disease never progressed into the second phase and the mice were not dying from pneumonia.

The mice did eventually die, but it took much longer and probably resulted from a bloodstream infection.

Goldman said the study indicated this protein is essential for the normal progression of pneumonic plague, and that without it the disease stalls in the first phase, perhaps giving antibiotics time to work.

The protein is a type called a protease that breaks down other proteins. Drugs called protease inhibitors targeting these proteins have been used against other infectious diseases, including AIDS.

According to the World Health Organization, about 1,000 to 3,000 cases of plague are reported every year with 10 to 15 cases in the United States every year.

Source: Bio-Bio Technology
SRI
'"/>




Page: 1 2

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...on to surgical treatment for rectal cancer may not... But the findings suggest that the radiation treat...tient's quality of life by reducing the rate of ca...l tumor site in the rectum. In about 15% to 45% of...
...dence of the disease was found to have been cut to...ressure in check. The study involving about 6,000 ...hat strokes were cut by at least a quarter among p...gs are inexpensive and easily available. Use of th...
...nd to support immunity in elderly, frail and patie...operation, rate of infection is a common risk, esp...searchers at the University of Pittsburgh report o...ch enhances the immune system in patients undergoi...
...e effects on the heart among the young and old.The...h have a diameter of less than ten micrometres. Th...n, by entering the circulation, especially in peop...ng to a new study by researchers at Harvard Univer...
Other Medicine News:
(Date:8/14/2008)..., Aug. 14 /- Pharmasset, In...al company committed to,discovering, developing an...tions, reported unaudited financial results for th...sset reported a net loss attributable to,common st...f $0.69 for the,quarter ended June 30, 2008, as co...
(Date:8/14/2008)..., Fla., Aug. 14 /- The Clinical Trial...t educating physicians,clinical coordinators, cli...nical trial. It will be held in Boca Raton at the ...stigators, clinical coordinators, monitors and,oth...ut how to incorporate,clinical trials into a pract...
(Date:8/14/2008)...velopment to begin in late 2008 or in early 2009 -...ll/ -- Nuvelo, Inc.,(Nasdaq: NUVO ) today announc...cept trial of NU172, demonstrating that the direct...d anticoagulation with a rapid,return toward basel...ty,profile., "NU172 has the potential to address ...
(Date:8/13/2008)...3 /- As biotechnology,phar...ly move clinical,trials beyond their own borders t...Europe and South America, complicated regulatory e...usiness, according to an analysis by,Aon Corporati...Map provides,those companies a visual representati...
Breaking Medicine Technology:Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 421 Days to Creating Your Dream Life Will be Unleashed on April 28 2008 16949 121 Days to Creating Your Dream Life Will be Unleashed on April 28 2008 16949 2Chromos provides shareholder update 4642 1Chromos provides shareholder update 4642 2Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4640 1Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4640 2Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4640 3Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4640 4Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4640 5Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4640 6Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 1823 1Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 1823 2
...J.--(BUSINESS WIRE)--Mar 29, 2007 - Cytogen,Corpor...resentation,of preclinical data at the 2007 Annual...search (AACR) taking place in Los Angeles,Califor...d on,preclinical studies that validate novel appro...n the Company,s proprietary,Abtides(TM) (Antigen-B...
...USINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceutica...y utilizing,innovative technology to fuel drug dis...s for central nervous system,disorders, today anno...ternational Congress on Schizophrenia Research, he...o Springs, Colorado.,Presentations will cover ACAD...
Other Medicine Technology:Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 2Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 3Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5
...essure Assessment and Management System provides a...l blood pressure and other key cardiovascular data...agement of patients. , ,Using a validated gene...ascending aortic blood pressure waveform from the ...
A system for all indications, can be used with the OrthoPilot surgical navigation system.
The humidity chamber maintains a moist environment during immunostaining procedures as well as other laboratory procedures requiring controlled incubation steps.
Used to remove wrinkles from sections and for reorientating embedded tissue.
Medicine Products: